文献速递免疫规划

两种四价脑膜炎球菌结合疫苗皮内注射分次剂量的安全性和免疫原性

Safety and immunogenicity of fractional dose intradermal injection of two quadrivalent conjugated meningococcal vaccines.
PubMed 文献 · Vaccine · 2018-05-16

本研究采用适应性剂量递增设计,将两种四价脑膜炎球菌结合疫苗(MenACWY-CRM197与MenACWY-TT)的不同分次剂量皮内注射给受试者,共纳入12人(平均25岁,范围19-48岁)。结果显示分次皮内接种似乎安全有效,MenACWY-TT的1/10和1/5剂量均达到对所有疫苗血清群的完全血清保护,而MenACWY-CRM197仅评估了1/10剂量且对A群血清保护不完全。

要点

  • MenACWY-TT的1/10和1/5分次剂量皮内接种均达到对所有疫苗血清群的完全血清保护。
  • MenACWY-CRM197的1/10剂量对A群血清保护不完全,对其他血清群完全保护。
  • 不良事件为轻度,未发生严重不良事件。

核心结论

  • 分次皮内接种四价脑膜炎球菌结合疫苗在这项小型剂量探索研究中似乎安全有效。
  • 破伤风类毒素结合疫苗(Nimenrix®)与CRM197结合疫苗(Menveo®)相比,抗体水平呈现更高趋势。
  • MenACWY-TT的1/5分次剂量似乎比1/10剂量产生更高的抗体水平。
  • 这些结果可用于更大规模的非劣效性研究。

研究设计与样本

  • 采用适应性剂量递增设计,将两种四价脑膜炎球菌结合疫苗(MenACWY-CRM197(Menveo®)和MenACWY-TT(Nimenrix®))的不同分次剂量皮内注射给连续4名受试者组成的组,起始剂量为原剂量的1/10。
  • 根据使用多重珠基检测(MIA)的中期血清学结果,在4-6个月后给予加强剂量。
  • 最终分析基于血清杀菌抗体滴度(rSBA)。
  • 共纳入12名受试者(平均25岁,范围19-48)。
  • 研究期间MenACWY-CRM197不可用,仅评估了1/10剂量。

主要发现

  • MenACWY-CRM197的1/10剂量导致对A群血清保护不完全,但对其他血清群完全保护。
  • MenACWY-TT的1/10和1/5分次剂量均导致对所有疫苗血清群的完全血清保护。
  • 接种后1个月,MenACWY-CRM197组的几何平均滴度较低且衰减更快。
  • 不良事件为轻度,未发生严重不良事件。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文称本研究为小型剂量探索研究(small dose finding study)。
  • 研究期间MenACWY-CRM197不可用,仅评估了1/10剂量。
  • 原文结论指出这些结果可用于更大规模的非劣效性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vaccination with conjugated meningococcal vaccines is the best way to prevent invasive meningococcal disease. Changes in serogroup epidemiology have led to the inclusion of quadrivalent vaccines in the national immunization programs of several countries, but vaccines are frequently in short supply. Intradermal administration has the potential to increase vaccine availability through dose reduction, without sacrificing efficacy. It has never before been investigated for glycoconjugate meningococcal vaccines. METHODS: Different fractional doses of two quadrivalent meningococcal conjugate vaccines (MenACWY-CRM197 (Menveo®) and MenACWY-TT (Nimenrix®)) were administered intradermally to sequential groups of 4 participants, according to an adaptive dose escalation design, starting at 1/10th of the original dose. Booster doses were given after 4-6 months based on interim serology results using a multiplex bead-based assay (MIA). Final analyses were based on serum bactericidal antibody titers (rSBA). RESULTS: A total of 12 subjects were enrolled (average 25 years old, range 19-48). MenACWY-CRM197 became unavailable during the course of the study and was only evaluated for a 1/10th dose. This dose resulted in less than complete seroprotection for serogroup A but complete protection against the other serogroups. MenACWY-TT was evaluated for a 1/10th and 1/5th dose level. Both fractional doses of MenACWY-TT resulted in complete seroprotection against all vaccine serogroups. Geometric mean titers 1 month after vaccination were lower and decayed faster in the MenACWY-CRM197 group. Adverse events were mild and there were no serious adverse events. CONCLUSION: Fractional intradermal vaccination against meningococcal disease with quadrivalent conjugate vaccine appears to be safe and effective in our small dose finding study. Tetanus toxoid conjugated vaccine (Nimenrix®) shows a trend towards higher antibody levels compared to CRM197-conjugated vaccine (Menveo®). The 1/5th fractional dose of MenACWY-TT appears to result in higher antibody levels than does the 1/10th dose. These results can be used for a larger non-inferiority study. This trial was registered in clinicaltrials.gov under NCT01782066.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Jonker EFF, van Ravenhorst MB, Berbers GAM, et al. Safety and immunogenicity of fractional dose intradermal injection of two quadrivalent conjugated meningococcal vaccines. Vaccine. 2018. PMID: 29778515. doi:10.1016/j.vaccine.2018.05.064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。